Fig. 1.

Overall survival from selected first-line therapies for metastatic melanoma. The graph shows 3-year overall survival rates for selected immunotherapies, targeted therapies and chemotherapies (5, 6, 44, 62, 127, 128). As there are differences between the selected studies in terms of entry criteria, as well as change over time in availability of second-line therapies, this graph is intended to illustrate the marked improvement in overall survival with recently FDA-approved immunotherapies and not intended for treatment decision-making. Ipi, ipilimumab; Nivo, nivolumab; Pembro, pembrolizumab; HD IL-2, high-dose IL-2; Dab, dabrafenib; tram, trametinib; DTIC = dacarbazine. Green indicates immune therapy; yellow indicates targeted therapy; red indicates chemotherapy.